• Atena Mahdavi, Amirmansour Alavi Naeini, Mohammadreza Najafi, Mohammadreza Maracy, and Mohammadreza Aghaye Ghazvini.
• Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
• Afr Health Sci. 2020 Jun 1; 20 (2): 984990984-990.

BackgroundThere is a limited amount of data regarding levetiracetam (LEV), an antiepileptic drug.ObjectiveThis study was conducted to assess the effect of LEV on antioxidant status and liver enzymes.MethodsIn this case-control study, 33 epileptic patients under treatment with LEV for at least 6 months were compared with 35 healthy subjects. We measured serum total antioxidant capacity (TAC), salivary superoxide dismutase (SOD), alanine aminoteransferase (ALT), and aspartate aminoteransferase (AST) levels in both groups. Dietary intakes were collected using a Food Frequency Questionnaire (FFQ).ResultThe level of TAC in the healthy subjects was significantly higher than it was in the patients (P=0.02), but the mean of ALT (P=0.02) and AST (P=0.03) was significantly higher in the patients in comparison with the controls. Mean salivary SOD showed no difference between the two groups. In the patients, the duration of drug use was inversely correlated with serum TAC (p=0.04) and had a direct correlation with ALT (p=0.01) and AST (p=0.03.).ConclusionThe results of our study indicated that LEV increased liver enzymes Also, treatment with this drug did not improve oxidative stress, but this could be due to the different in the dietary antioxidant intake. Routine screening of the liver and antioxidant enzymes in patients with chronic use of LEV is recommended.© 2020 Mahdavi A et al.

25 keywords...

hide…